A SYSTEMATIC REVIEW ON PARALLEL EFFECT ON THIAZOLIDINEDIONES AND SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS
Mrs. Yachita Jokhi1, Dr. Priyanka Patil2, Dr. Nidhi Chauhan3, Dr. Chainesh Shah4, Dr. Umesh Upadhyay5
1Ph.D. Scholar, Department of Pharmaceutical Quality Assurance, 2Director & Professor, 4Research Coordinator & Professor, 5Dean & Professor,Faculty of Pharmacy, Sigma University, Vadodara, India
3Professor, Laxminarayandev College of Pharmacy, Bharuch, India
ABSTRACT: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are medications mainly used for decreasing elevated blood glucose levels by offering unique mechanism of action by blocking glucose reabsorption into the bloodstream, leading to increased urinary excretion of glucose and effectively decreasing blood sugar levels. On other side thiazolidinediones are a class of oral anti-diabetic drugs improve insulin sensitivity by binding peroxisome proliferator-activated receptor-gamma receptor (PPAR-γ) in fat cells (adipocytes) and lowering circulating fat concentrations and thus enhance sensitivity to insulin and lowering the blood glucose level. So, combination of lobeglitazone and dapagliflozin are effective strategy for managing type 2 diabetes mellitus (T2DM). Lobeglitazone is a thiazolidinedione that improves insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that helps reduce blood glucose levels by promoting glucose excretion through urine. Clinical Studies have shown that this combination can lead to significant improvements in glycemic control, including reductions in HbA1c levels, body weight, and blood pressure. Additionally, the combination therapy has been found to decrease postprandial hyperglycemia more effectively than dapagliflozin alone.
KEYWORDS: Thiazolidinediones, sodium-glucose co-transporter 2 (SGLT2) inhibitors, Dapagliflozin, Lobeglitazone Sulphate, Hyperglycemia.